Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Development of Carvedilol Nanoformulation-Loaded Poloxamer-Based In Situ Gel for the Management of Glaucoma
oleh: Bjad K. Almutairy, El-Sayed Khafagy, Amr Selim Abu Lila
| Format: | Article |
|---|---|
| Diterbitkan: | MDPI AG 2023-12-01 |
Deskripsi
The objective of the current study was to fabricate a thermosensitive in situ gelling system for the ocular delivery of carvedilol-loaded spanlastics (CRV-SPLs). In situ gel formulations were prepared using poloxamer analogs by a cold method and was further laden with carvedilol-loaded spanlastics to boost the precorneal retention of the drug. The gelation capacity, rheological characteristics, muco-adhesion force and in vitro release of various in situ gel formulations (CS-ISGs) were studied. The optimized formula (F2) obtained at 22% <i>w</i>/<i>v</i> poloxamer 407 and 5% <i>w</i>/<i>v</i> poloxamer 188 was found to have good gelation capacity at body temperature with acceptable muco-adhesion properties, appropriate viscosity at 25 °C that would ease its ocular application, and relatively higher viscosity at 37 °C that promoted prolonged ocular residence of the formulation post eye instillation and displayed a sustained in vitro drug release pattern. Ex vivo transcorneal penetration studies through excised rabbit cornea revealed that F2 elicited a remarkable (<i>p</i> ˂ 0.05) improvement in CRV apparent permeation coefficient (P<sub>app</sub> = 6.39 × 10<sup>−6</sup> cm/s) compared to plain carvedilol-loaded in situ gel (CRV-ISG; P<sub>app</sub> = 2.67 × 10<sup>−6</sup> cm/s). Most importantly, in normal rabbits, the optimized formula (F2) resulted in a sustained intraocular pressure reduction and a significant enhancement in the ocular bioavailability of carvedilol, as manifested by a 2-fold increase in the AUC<sub>0–6h</sub> of CRV in the aqueous humor, compared to plain CRV-ISG formulation. To sum up, the developed thermosensitive in situ gelling system might represent a plausible carrier for ophthalmic drug delivery for better management of glaucoma.